{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:24:06Z","timestamp":1792167846719,"version":"4.4.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Efgartigimod, a first-in-class neonatal Fc receptor (FcRn) antagonist, has transformed the therapeutic landscape of generalized myasthenia gravis (gMG). This review synthesizes evidence from pivotal trials to real-world applications. The phase 3 ADAPT trial demonstrated rapid, clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores in anti-acetylcholine receptor antibody-positive (AChR-Ab+) patients, with a favorable safety profile. Long-term extension studies confirmed reproducible efficacy and sustained safety across multiple treatment cycles. Subsequent research optimized dosing through flexible, individualized regimens and a subcutaneous formulation, enhancing patient convenience. Extensive real-world evidence validates these findings across diverse populations, including antibody-negative patients, those with acute exacerbations or myasthenic crisis, and thymoma-associated MG, consistently showing rapid response and steroid-sparing effects. When real-world evidence is stratified by antibody status, thymic pathology, and age at onset, efgartigimod shows consistent benefits across most subgroups, including MuSK-positive and seronegative patients. Emerging data suggest immunomodulatory effects beyond IgG reduction, influencing B-cell populations and gene expression profiles. While comparative efficacy against other novel biologics (complement inhibitors, other FcRn antagonists) remains under investigation through indirect analyses, efgartigimod\u2019s rapid onset, cyclical administration allowing drug holidays, and broad applicability distinguish it. Distinct biomarker profiles are emerging for FcRn blockade versus complement inhibition, with the former linked to measurable changes in IgG subclasses and immune cell phenotypes. Ongoing research focuses on optimizing patient selection, exploring combination therapies, and expanding applications to other IgG-mediated autoimmune diseases. Efgartigimod represents a cornerstone of targeted immunotherapy in MG, offering personalized, effective, and well-tolerated disease management.<\/jats:p>","DOI":"10.3389\/fneur.2026.1813230","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:41Z","timestamp":1781065781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Lingyu","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Intensive Care Unit, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaping","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjing","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglong","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The People\u2019s Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"725700","DOI":"10.3389\/fneur.2021.725700","article-title":"Efficacy and safety of immunotherapies in refractory myasthenia gravis: a systematic review and meta-analysis","volume":"12","author":"Feng","year":"2021","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13643-025-02859-3","article-title":"Comparative efficacy and acceptability of novel biologics in the treatment of myasthenia gravis: systematic review and network meta-analysis of randomized trials","volume":"14","author":"Guan","year":"2025","journal-title":"Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","article-title":"FcRn inhibitor therapies in neurologic diseases","volume":"38","author":"Alfaidi","year":"2024","journal-title":"CNS Drugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1007\/s10072-024-07460-5","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod alfa in generalised myasthenia gravis: a profile of its use","volume":"37","author":"Heo","year":"2023","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1080\/1744666X.2022.2136167","article-title":"Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective","volume":"18","author":"Suzuki","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacc\u00e0","year":"2023","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2024","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e16098","DOI":"10.1111\/ene.16098","article-title":"Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study","volume":"31","author":"Bril","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1502721","DOI":"10.3389\/fimmu.2024.1502721","article-title":"Cutoffs on severity metrics for minimal manifestations or better status in patients with generalized myasthenia gravis","volume":"15","author":"Shimatani","year":"2024","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/acn3.70051","article-title":"ADAPT NXT: fixed cycles or every-other-week IV efgartigimod in generalized myasthenia gravis","volume":"12","author":"Habib","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e00378","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.11477\/mf.188160960770010067","article-title":"Subcutaneous injection of efgartigimod, a new therapeutic agent for generalized myasthenia gravis","volume":"77","author":"Uzawa","year":"2025","journal-title":"Brain Nerve"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40120-025-00748-4","article-title":"Real-world experience with FcRn inhibitors efgartigimod and rozanolixizumab in myasthenia gravis: administration in multiple cycles and transition from intravenous to subcutaneous formulation","volume":"14","author":"Yoshikawa","year":"2025","journal-title":"Neurol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40268-024-00490-6","article-title":"Pharmacokinetics, pharmacodynamics, and safety of intravenous efgartigimod and subcutaneous efgartigimod PH20 in healthy Chinese participants","volume":"24","author":"Jing","year":"2024","journal-title":"Drugs R D"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK'S first real-world experience","volume":"96","author":"Moniz Dion\u00edsio","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mus.27974","article-title":"Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"68","author":"Katyal","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e200276","DOI":"10.1212\/CPJ.0000000000200276","article-title":"Therapeutic responses to efgartigimod for generalized myasthenia gravis in Japan","volume":"14","author":"Suzuki","year":"2024","journal-title":"Neurol Clin Pract"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-world experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"J Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/mus.28334","article-title":"Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: clinical experience at a single center","volume":"71","author":"Silvestri","year":"2025","journal-title":"Muscle Nerve"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"123652","DOI":"10.1016\/j.jns.2025.123652","article-title":"Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis","volume":"477","author":"Goyal","year":"2025","journal-title":"J Neurol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/14712598.2025.2490063","article-title":"Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance","volume":"25","author":"Teranishi","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00415-025-13367-8","article-title":"Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study","volume":"272","author":"Zhu","year":"2025","journal-title":"J Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1715486","DOI":"10.3389\/fneur.2025.1715486","article-title":"Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective analysis of predictive factors","volume":"16","author":"Niu","year":"2025","journal-title":"Front Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/mjt.0000000000002052","article-title":"Novel Therapies for Generalized Myasthenia Gravis: Insights into FcRn and Complement Inhibition","volume":"33","author":"Samara","year":"2026","journal-title":"Am J Ther"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","article-title":"Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-ab+) generalized myasthenia gravis: indirect treatment comparison","volume":"41","author":"van Steen","year":"2024","journal-title":"Adv Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","article-title":"The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis","volume":"271","author":"Li","year":"2024","journal-title":"J Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1007\/s12325-024-03014-5","article-title":"Risk-benefit analysis of novel treatments for patients with generalized myasthenia gravis","volume":"41","author":"Smith","year":"2024","journal-title":"Adv Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.18553\/jmcp.2024.30.6.517","article-title":"Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"30","author":"Lien","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40120-025-00873-0","article-title":"Oral corticosteroid and nonsteroidal immunosuppressant therapy use in patients with myasthenia gravis receiving ravulizumab, eculizumab, or efgartigimod in the USA","volume":"15","author":"Sacc\u00e0","year":"2026","journal-title":"Neurol Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"17562864251326778","DOI":"10.1177\/17562864251326778","article-title":"Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis","volume":"18","author":"Zhou","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"17562864251388019","DOI":"10.1177\/17562864251388019","article-title":"Open-label study of efgartigimod in seronegative myasthenia gravis","volume":"18","author":"Khateb","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.jtho.2025.04.014","article-title":"Perioperative safety and efficacy of efgartigimod for thymoma-associated myasthenia gravis: a prospective, multicenter, phase II clinical trial","volume":"20","author":"Wang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"109241","DOI":"10.1016\/j.ijscr.2024.109241","article-title":"Efgartigimod is a new option for the treatment of thymoma associated myasthenia gravis: a case report","volume":"115","author":"Wang","year":"2024","journal-title":"Int J Surg Case Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1627584","DOI":"10.3389\/fimmu.2025.1627584","article-title":"Efgartigimod for patients with thymoma associated generalized myasthenia gravis during the perioperative period: a four-case report","volume":"16","author":"Ren","year":"2025","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1579859","DOI":"10.3389\/fimmu.2025.1579859","article-title":"Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1685233","DOI":"10.3389\/fimmu.2025.1685233","article-title":"Efgartigimod for generalized myasthenia gravis in the extreme elderly (\u226580 years): a multicenter retrospective real-world study","volume":"16","author":"Hong","year":"2025","journal-title":"Front Immunol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"8287","DOI":"10.1007\/s00210-025-03954-x","article-title":"A systematic review of efgartigimod as an effective treatment for myasthenic crisis","volume":"398","author":"Tang","year":"2025","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1418503","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12883-025-04063-1","article-title":"Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neonatal intensive care unit","volume":"25","author":"Shi","year":"2025","journal-title":"BMC Neurol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"578431","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: a single-center case series","volume":"395","author":"Hong","year":"2024","journal-title":"J Neuroimmunol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e00730","DOI":"10.1016\/j.neurot.2025.e00730","article-title":"Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: a retrospective cohort study","volume":"22","author":"Guo","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e200455","DOI":"10.1212\/NXI.0000000000200455","article-title":"Unknown immunoregulatory effects of FcRn inhibition by efgartigimod in myasthenia gravis: a new mechanism of action beyond IgG reduction","volume":"12","author":"Tarasco","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e70391","DOI":"10.1111\/cns.70391","article-title":"Efficacy and safety of efgartigimod for patients with myasthenia gravis in a real-world cohort of 77 patients","volume":"31","author":"Hao","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/acn3.70261","article-title":"Olink proteomics analysis reveals heterogeneous responses to FcRn blockade in anti-AChR antibody-positive myasthenia gravis: FGF-19 as a novel biomarker","volume":"13","author":"Luo","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e70746","DOI":"10.1002\/cns.70746","article-title":"Development and external validation of a multivariable model to predict early minimal symptom expression response in adult generalized myasthenia gravis patients treated with efgartigimod","volume":"32","author":"Yang","year":"2026","journal-title":"CNS Neurosci Ther"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e70627","DOI":"10.1111\/cns.70627","article-title":"Dynamic changes in peripheral immune cells during efgartigimod treatment in naive generalized myasthenia gravis","volume":"31","author":"Wang","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2586335","DOI":"10.1080\/21645515.2025.2586335","article-title":"Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: a disproportionality analysis based on the FAERS database","volume":"21","author":"Liu","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2147\/CLEP.S514738","article-title":"Post-marketing safety concerns with efgartigimod alfa: a pharmacovigilance analysis based on the Food and Drug Administration adverse event reporting system database","volume":"17","author":"Huang","year":"2025","journal-title":"Clin Epidemiol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1409480","DOI":"10.3389\/fimmu.2024.1409480","article-title":"Efgartigimod-associated Kaposi's varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review","volume":"15","author":"Ge","year":"2024","journal-title":"Front Immunol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/08916934.2022.2104261","article-title":"Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis","volume":"55","author":"Guptill","year":"2022","journal-title":"Autoimmunity"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2470542","DOI":"10.1080\/21645515.2025.2470542","article-title":"Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models","volume":"21","author":"Warang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/011570159X366227250716054651","article-title":"A prospective clinical trial of efgartigimod for new-onset generalized myasthenia gravis","volume":"23","author":"Ma","year":"2025","journal-title":"Curr Neuropharmacol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.2147\/JIR.S513986","article-title":"Efgartigimod followed by telitacicept in adult generalized myasthenia gravis: a retrospective case series","volume":"18","author":"Zhang","year":"2025","journal-title":"J Inflamm Res"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1400459","DOI":"10.3389\/fimmu.2024.1400459","article-title":"Case report: a highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/biomedicines13122975","article-title":"Efgartigimod for generalized myasthenia gravis and beyond: a narrative review of its pharmacological profile, clinical utility, and expanding applications","volume":"13","author":"Mansour","year":"2025","journal-title":"Biomedicine"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","article-title":"Current drug treatment of myasthenia gravis","volume":"36","author":"Vanoli","year":"2023","journal-title":"Curr Opin Neurol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1756286421997381","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1813230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:43Z","timestamp":1781065783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1813230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":65,"alternative-id":["10.3389\/fneur.2026.1813230"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1813230","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1813230"}}